Research programme: anti-phosphatidylserine monoclonal antibodies - Peregrine Pharmaceuticals

Drug Profile

Research programme: anti-phosphatidylserine monoclonal antibodies - Peregrine Pharmaceuticals

Alternative Names: 2aG4; Anti-phosphatidylethanolamine monoclonal antibodies - Peregrine; Anti-phospholipid monoclonal antibodies - Peregrine; ch1N11; PGN-502; PGN-503; PGN-504; Truncated tissue factors - Peregrine; Vascular targeting agents - Peregrine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Peregrine Pharmaceuticals
  • Class Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Diagnostic imaging enhancers; Immunostimulants; Magnetic resonance imaging enhancers; Phosphatidylserine receptor antagonists; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma; Non-small cell lung cancer
  • No development reported Brain cancer; Breast cancer; Cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top